Advertisement
Screener

EQUILLIUM, INC. (EQ) Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions

2.8 / 5 stars · 68/120 Roast Me

EQUILLIUM, INC. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions

EQUILLIUM, INC. (EQ) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $271.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.

Financial Statements › Notes › Income Taxes › Income Tax Uncertainties

us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-03-25

  • EQUILLIUM, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $271.00K, a 2.26% increase from fiscal 2024.
  • EQUILLIUM, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $265.00K, a 134.51% increase from fiscal 2023.
  • EQUILLIUM, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $113.00K, a 71.17% decline from fiscal 2022.
  • EQUILLIUM, INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $392.00K, a 29.24% decline from fiscal 2021.
Period endUnrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 10 monthUnrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 monthUnrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month as first filed
2025-12-31$271.00K
10-K · filed 2026-03-25
2024-12-31$265.00K
10-K · filed 2026-03-25
2023-12-31$113.00K
10-K · filed 2025-03-27
2022-12-31$392.00K
10-K · filed 2024-03-25
2021-12-31$554.00K
10-K · filed 2023-03-23
2020-12-31$319.00K
10-K · filed 2022-03-23
2019-12-31$271.00K
10-K · filed 2021-03-24
2018-12-31$81.00K
10-K · filed 2020-03-26
$81.79K
10-K · filed 2019-03-27
2017-12-31$18.85K
10-K · filed 2019-03-27

Similar stocks

Stock NameCountryMarket CapPE Ratio
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
GENELUX Corp (GNLX)United States$0.110B-3.83
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
ProMIS Neurosciences Inc. (PMN)$0.102B
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49